Non-Invasive Protein Biomarkers Study for Diagnosis and Monitoring of Endometriosis in Women Ages 18 to 45

What this Trial Is About

Endometriosis is a condition where tissue similar to the uterus lining grows outside the uterus, often causing pain and infertility. The diagnosis currently relies on invasive procedures like laparoscopy and biopsy. This research aims to evaluate whether two proteins, Synuclein Gamma SNCG and B-Cell Lymphoma 6 BCL6, measurable in blood and menstrual fluid, can be used as non-invasive markers to diagnose or monitor endometriosis. The study involves collecting blood and menstrual fluid samples from women diagnosed with endometriosis and from healthy controls aged 18 to 45. Patients with endometriosis will be followed after medical or surgical treatment, with samples taken at baseline, 3 months, and 6 months post-treatment. SNCG and BCL6 protein levels will be measured using specific ELISA tests to compare differences between groups and changes after treatment. Participants will provide samples at multiple time points, and researchers will analyze protein concentrations to assess their potential as diagnostic or prognostic indicators. The main outcome is measuring SNCG and BCL6 levels at baseline and approximately 3 months after treatment in patients with endometriosis and at baseline in controls. The study is observational, involves women of reproductive age, and will run until 2027, with ongoing monitoring of protein levels over time.

Biomarkers for Endometriosis